BERTOZZI, IRENE
 Distribuzione geografica
Continente #
NA - Nord America 4.465
EU - Europa 435
AS - Asia 410
AF - Africa 6
SA - Sud America 2
OC - Oceania 1
Totale 5.319
Nazione #
US - Stati Uniti d'America 4.463
SG - Singapore 198
IT - Italia 183
CN - Cina 166
FI - Finlandia 61
FR - Francia 46
SE - Svezia 46
VN - Vietnam 32
GB - Regno Unito 31
DE - Germania 20
IE - Irlanda 15
NL - Olanda 15
CH - Svizzera 6
IN - India 5
MD - Moldavia 3
AR - Argentina 2
CA - Canada 2
EG - Egitto 2
HK - Hong Kong 2
IL - Israele 2
JP - Giappone 2
UA - Ucraina 2
ZW - Zimbabwe 2
BE - Belgio 1
BG - Bulgaria 1
ES - Italia 1
GR - Grecia 1
ID - Indonesia 1
NZ - Nuova Zelanda 1
PH - Filippine 1
PT - Portogallo 1
RO - Romania 1
SC - Seychelles 1
SM - San Marino 1
TN - Tunisia 1
TW - Taiwan 1
Totale 5.319
Città #
Fairfield 994
Woodbridge 444
Houston 424
Ashburn 359
Seattle 351
Cambridge 342
Ann Arbor 328
Wilmington 257
Chandler 191
Singapore 162
San Diego 106
Princeton 74
Padova 69
Medford 67
Des Moines 44
Beijing 39
Helsinki 34
Dong Ket 32
Nanjing 27
Santa Clara 26
Jacksonville 16
Dublin 15
Boardman 13
Roxbury 11
Jinan 9
Shenyang 9
Hebei 8
Cagliari 6
Falls Church 6
Legnaro 6
London 6
Milan 6
New York 6
Paris 6
Borås 5
Nanchang 5
Verona 5
Dronten 4
Jiaxing 4
Kilburn 4
Ningbo 4
Perugia 4
Phoenix 4
Tianjin 4
Cervignano del Friuli 3
Chisinau 3
Monselice 3
Norwalk 3
Ogden 3
Zurich 3
Angri 2
Bridgend 2
Buenos Aires 2
Castellammare di Stabia 2
Changsha 2
Chicago 2
Delhi 2
Frankfurt am Main 2
Genoa 2
Harare 2
Hefei 2
Hong Kong 2
Ivrea 2
Kharkiv 2
Kunming 2
Lanzhou 2
Monza 2
New Bedfont 2
Orbetello 2
Palermo 2
Pescara 2
Rockville 2
Rome 2
Taiyuan 2
Tokyo 2
Vechta 2
Acton 1
Alert Bay 1
Amsterdam 1
Ancona 1
Auckland 1
Bari 1
Borgo Maggiore 1
Brescia 1
Castel Maggiore 1
Chennai 1
Chiswick 1
Dallas 1
Duino-Aurisina 1
Fremont 1
Fulham 1
Groningen 1
Hangzhou 1
Hounslow 1
Indiana 1
Islington 1
Jakarta 1
Kensington 1
Las Vegas 1
Limbiate 1
Totale 4.630
Nome #
A randomized, double-blind trial of three aspirin regimens to optimize antiplatelet therapy in essential thrombocythemia 132
Thrombotic risk correlates with mutational status in true-essential thrombocythemia 130
Polypharmacy in older people: lessons from 10 years of experience with the REPOSI register 126
Systemic mastocytosis and essential thrombocythemia: Case report and literature overview 121
Practice-relevant revision of IPSET-thrombosis based on 1019 patients with WHO-defined essential thrombocythemia 118
Bone marrow histology for the diagnosis of essential thrombocythemia in children: a multi-center Italian study 116
Cardiovascular Events and Intensity of Treatment in Polycythemia Vera 109
Activated FVII levels in factor VII Padua (Arg304Gln) coagulation disorder and in true factor VII deficiency: a study in homozygotes and heterozygotes 107
Link between von Willebrand factor multimers, relapses and coronary microcirculation in patients with thrombotic thrombocytopenic purpura in remission 106
Hospital Care of Older Patients With COPD: Adherence to International Guidelines for Use of Inhaled Bronchodilators and Corticosteroids 101
Two novel missense mutations in EPOR gene causes erythrocytosis in two unrelated patients 95
A lower intensity of treatment may underlie the increased risk of thrombosis in young patients with masked polycythaemia vera 94
Masked polycythemia Vera (mPV): Results of an international study 93
Prevalence of use and appropriateness of antidepressants prescription in acutely hospitalized elderly patients 93
A 40-years-old man with recurrent fainting, hypotension, lower limb edema and oliguria with body weight gain and secondary erythrocytosis 90
Risk factors for arterial and venous thrombosis in WHO-defined essential thrombocythemia: an international study of 891 patients 90
Need for Deprescribing in Hospital Elderly Patients Discharged with a Limited Life Expectancy: The REPOSI Study 90
Patterns of infections in older patients acutely admitted to medical wards: data from the REPOSI register 89
Effect of busulfan on JAK2V617F allele burden. 88
Idiopathic erythrocytosis: a study of a large cohort with a long follow-up 88
Prevalence, characteristics and treatment of chronic pain in elderly patients hospitalized in internal medicine wards 88
Initial bone marrow reticulin fibrosis in polycythemia vera exerts an impact on clinical outcome 87
Pregnancy oucotcome and management of 25 pregnancies in women with polycythemia vera 85
Impact of mutational status on pregnancy outcome in patients with essential thrombocytemia 83
Histology of the spleen in Immune Thrombocytopenia: clinical-pathological characterization and prognostic implications 83
Thrombotic and hemorrhagic complications in idiopathic erythrocytosis 81
HFE mutations in idiopathic erythrocytosis 81
Role of blood cells dynamism on hemostatic complications in low-risk patients with essential thrombocythemia. 81
Hydroxyurea-related toxicity in 3,411 patients with Ph'-negative MPN 81
Mortality rate and risk factors for gastrointestinal bleeding in elderly patients 79
Drug–drug interactions involving CYP3A4 and p-glycoprotein in hospitalized elderly patients 78
Disease characteristics and clinical outcome in young adults with essential thrombocythemia versus early /prefibrotic primary myelofibrosis. 77
The multifaceted spectrum of liver cirrhosis in older hospitalised patients: analysis of the REPOSI registry 77
Pregnancy complications predict thrombotic events in young women with essential thrombocythemia. 76
Incidence and risk factors for bleeding in 1104 patients with essential thrombocythemia or prefibrotic myelofibrosis diagnosed according to the 2008 WHO criteria. 75
In contemporary patients with polycythemia vera, rates of thrombosis and risk factors delineate a new clinical epidemiology 75
Are all cases of paediatric essential thrombocythaemia really myeloproliferative neoplasms? Analysis of a large cohort 75
Thromboses and hemorrhages are common in MPN patients with high JAK2V617F allele burden 74
Leukocytosis as an important risk factor for arterial thrombosis in WHO-defined early/prefibrotic myelofibrosis: An international study of 264 patients 74
A prognostic model to predict survival in 867 World Health Organization-defined essential thrombocythemia at diagnosis: a study by the International Working Group on Myelofibrosis Research and Treatment. 73
The Aspirin Regimens in Essential Thrombocythemia (ARES) phase II randomized trial design: Implementation of the serum thromboxane B2assay as an evaluation tool of different aspirin dosing regimens in the clinical setting 71
Survival and prognosis among 1545 patients with contemporary polycythemia vera: an international study 70
Biomolecular and histological features in pediatric essential thrombocythemia: adequacy of who diagnostic criteria 70
Antibiotic use and associated factors in a large sample of hospitalised older people 69
Prognostic relevance of glomerular filtration rate estimation obtained through different equations in hospitalized elderly patients 69
Survival and disease progression in essential thrombocythemia are significantly influenced by accurate morphologic diagnosis: an international study 68
Thrombotic events in patients with congenital prekallikrein deficiency: A critical evaluation of all reported cases 68
Blood tests may predict early primary myelofibrosis in patients presenting with essential thrombocythemia 67
Development and validation of an International Prognostic Score of thrombosis in WHO-Essential Thrombocythemia (IPSET-thrombosis). 66
Discrepant ratios of arterial vs. venous thrombosis in hemophilias A and B as compared to FVII deficiency 66
Pattern of comorbidities and 1-year mortality in elderly patients with COPD hospitalized in internal medicine wards: data from the RePoSI Registry 65
Benefit-risk profile of cytoreductive drugs along with antiplatelet and antithrombotic therapy after transient ischemic attack or ischemic stroke in myeloproliferative neoplasms 64
Bleeding manifestations apparently unrelated to coagulation or other organic disorders: A tentative classification and diagnostic clues 64
Disability, and not diabetes, is a strong predictor of mortality in oldest old patients hospitalized with pneumonia 64
Contemporary management of essential thrombocythemia in children 62
Living alone as an independent predictor of prolonged length of hospital stay and non-home discharge in older patients 58
Sex-Differences in the Pattern of Comorbidities, Functional Independence, and Mortality in Elderly Inpatients: Evidence from the RePoSI Register 58
Congenital FVII deficiency and thrombotic events after replacement therapy 57
Discrepant ratios of arterial versus venous thrombosis in hemophilia A as compared with hemophilia B 55
Underdiagnosis and undertreatment of osteoporotic patients admitted in internal medicine wards in Italy between 2010 and 2016 (the REPOSI Register) 54
Pain and Frailty in Hospitalized Older Adults 51
Prevalence and Causes of Anemia in Hospitalized Patients: Impact on Diseases Outcome 49
Inappropriate prescription of benzodiazepines in acutely hospitalized older patients 44
Extremely Old Patients Hospitalized in Internal Medicine: What about Their Anemia? 37
Platelet-Derived Microparticles Bearing PF4 and Anti-GAGS Immunoglobulins in Patients with Sepsis 34
Clinical effect of CALR allele burden in patients with essential thrombocythemia 30
A NEW SUSPECTED CAUSE OF ERYTHROCYTOSIS: EPAS1 MUTATIONS ASSOCIATED WITH MUTATIONS IN OTHER GENES 24
Appropriateness of packed red blood cells transfusions in chronic anemic patients in the emergency department: the TRANSFUS-ED retrospective analysis 22
Thrombopoietin receptor agonists increase splenic regulatory T-cell numbers in immune thrombocytopenia 19
Clinical features and outcomes of elderly hospitalised patients with chronic obstructive pulmonary disease, heart failure or both 16
Association of Platelet Thromboxane Inhibition by Low-Dose Aspirin With Platelet Count and Cytoreductive Therapy in Essential Thrombocythemia 16
ERYTHROCYTOSIS AND FAMILIARITY: COEXISTANCE OF MULTIPLE MUTATIONS 15
IDIOPATHIC ERYTHROCYTOSIS WITH THROMBOTIC COMPLICATIONS HAS AN ALTERED BIOMOLECULAR PROFILE 15
What changed in the Italian internal medicine and geriatric wards during the lockdown 15
Hyperglycemia at admission, comorbidities, and in-hospital mortality in elderly patients hospitalized in internal medicine wards: data from the RePoSI Registry 15
Essential thrombocythemia in children and adolescents 12
Assessment of the efficacy and tolerability of ruxolitinib for the treatment of myelofibrosis patients in a real-life setting: An Italian MYNERVA Project 11
Targeted NGS analysis reveals a complex genetic background of idiopathic erythrocytosis in a large Venetian family 10
Coexistence of multiple gene variants in some patients with erythrocytoses: Multiple gene variants in erythrocytosis 9
Statins, ACE/ARBs drug use, and risk of pneumonia in hospitalized older patients: a retrospective cohort study 9
Prescription appropriateness of anti-diabetes drugs in elderly patients hospitalized in a clinical setting: evidence from the REPOSI Register 9
null 9
Antihypertensive treatment changes and related clinical outcomes in older hospitalized patients 8
The impact of thrombosis on probabilities of death and disease progression in polycythemia vera: a multistate transition analysis of 1,545 patients 2
Essential Thrombocythemia in Children and Adolescents 2
Long-term pharmacodynamic and clinical effects of twice- versus once-daily low-dose aspirin in essential thrombocythemia: The ARES trial 1
Totale 5.428
Categoria #
all - tutte 22.423
article - articoli 21.612
book - libri 0
conference - conferenze 0
curatela - curatele 0
other - altro 0
patent - brevetti 0
selected - selezionate 0
volume - volumi 0
Totale 44.035


Totale Lug Ago Sett Ott Nov Dic Gen Feb Mar Apr Mag Giu
2019/2020931 0 0 0 84 121 81 101 137 163 82 127 35
2020/20211.203 84 108 85 62 58 32 12 90 141 149 83 299
2021/20221.043 77 73 94 95 45 113 46 101 99 42 61 197
2022/2023500 133 16 4 27 82 70 3 52 54 19 26 14
2023/2024351 15 50 47 36 12 20 19 26 15 4 44 63
2024/2025318 10 161 93 54 0 0 0 0 0 0 0 0
Totale 5.428